论文部分内容阅读
目的观察极低剂量培哚普利/吲达帕胺复合制剂(商品名:百普乐)治疗原发性高血压患者的降压疗效及安全性。方法门诊原发性高血压患者经2周的安慰剂选择期后,进入12周随机、双盲平行组治疗期,采用随机、双盲、吲达帕胺缓释剂(商品名:纳催离)作对照。结果治疗后百普乐组患者血压由治疗前的(141.2±9.0)?(97.3±3.0)mmHg下降至(125.9±7.2)?(83.0±5.2)mmHg,有效率91.3%;纳催离组血压由治疗前的(144.1±11.9)?(99.6±4.4)mmHg下降至(125.5±11.3)?(81.9±7.5)mmHg,有效率89.9%。两组经治疗后血压均有效下降(均P<0.001)。百普乐组患者咳嗽发生率20.8%,因不能耐受而退出1例(4.2%);纳催离组低钾血症发生率为25.0%。结论百普乐治疗原发性高血压安全有效。
Objective To observe the antihypertensive effect and safety of the combination of a very low dosage of perindopril / indapamide compound (product name: Buprolol) in patients with essential hypertension. Methods Outpatients with essential hypertension were given randomized, double-blind and indapamide sustained-release agents (trade name: Natrium release ) As a control. Results After treatment, the blood pressure decreased from (141.2 ± 9.0) ((97.3 ± 3.0) mmHg before treatment to (125.9 ± 7.2) ((83.0 ± 5.2) mmHg, with an effective rate of 91.3% From (144.1 ± 11.9) ((99.6 ± 4.4) mmHg before treatment to (125.5 ± 11.3)? (81.9 ± 7.5) mmHg, the effective rate was 89.9%. After treatment, blood pressure decreased significantly in both groups (all P <0.001). Buprolol group patients with cough rate of 20.8%, due to intolerance and exit in 1 case (4.2%); satisfied with the group of hypokalemia incidence of 25.0%. Conclusion Buprolile is safe and effective in treating essential hypertension.